Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Monetary Versatility: Get ready for Life's Unforeseen Difficulties - 2Flash flooding causes highways to close to and from Eilat
- 3The most effective method to Distinguish the Best Material Organization in Your Space
- 4First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- 5Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
- Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
- The Ascent of Rousing Pioneers Who Formed History
- 6 Well known Ladies' Fragrances On the planet
- The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Earth's newfound 'episodic-squishy lid' may guide our search for habitable worlds
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
